24th Int'l Prostate Cancer Update

VAIL, CO USA (UroToday.com) - Presented by Thomas P. Kole, Leonard N. Chen, Joy S. Kim, Rudy Moures, Thomas Young, Siyuan Lei, Simeng Suy, Anatoly Dritschilo, John H. Lynch, and Sean P. Collins at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

VAIL, CO USA (UroToday.com) - Presented by E. Francisco G. La Rosa, MD, Cliff Jones, DDS, Paul Arangua, E. David Crawford, MD, and Leander Van Neste, PhD at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

VAIL, CO USA (UroToday.com) - Presented by Joe M. O’Sullivan, Dimitris Voliotis, Dag Clement Johannessen, Anders Widmark, Isabel Syndikus, Nicholas James, Marcos Dall’Oglio, Ingvild Haugen, Andrew Cross, Jose Garcia- Vargas, and Nicholas Vogelzang at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

VAIL, CO USA (UroToday.com) - Presented by Peter Hoskin, Mona Wahba, John Logue, David Bottomley, Sten Nilsson, Fang Fang, Jose Garcia-Vargas, Karin Staudacher, Paul Cislo, Jonathan Reuning-Scherer, and Christopher Parker at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

VAIL, CO USA (UroToday.com) - Presented by E. David Crawford, Neal Shore, Celestia Higano, Anders Neijber and Vladimir Yankov at the 24th International Prostate Cancer Update - February 19 - 22, 2014 - Cascade Conference Center - Vail, Colorado USA

VAIL, CO USA (UroToday.com) - Introduction and Objective: A number of new diagnostic assays are being developed to improve risk stratification in prostate cancer (PCa), but their performance in “real-life” clinical practice remains to be determined.

VAIL, CO USA (UroToday.com) - Introduction: The introduction of breast-sparing surgery (i.e., “lumpectomy”) revolutionized the management of breast cancer. The use of lumpectomy showed that quality of life could be optimized without compromising treatment efficacy.

VAIL, CO USA (UroToday.com) - Background: Radium-223 is the first alpha-emitter approved by both the US Food and Drug Administration and European Commission for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastases.

VAIL, CO USA (UroToday.com) - Light interacts with biological tissue in a variety of ways. The optical properties of tissues are determined by their molecular composition and cellular morphology.

VAIL, CO USA (UroToday.com) - Background: For men with prostate cancer requiring androgen suppression, intermittent androgen deprivation (IAD) has been proposed as an alternative to continuous androgen deprivation (CAD).

VAIL, CO USA (UroToday.com) - Background: Two oral agents have recently been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC): abiraterone acetate (AA) combined with prednisone (P) for treatment of patients with mCRPC and enzalutamide (ENZ) for patients with mCRPC previously treated with docetaxel.

VAIL, CO USA (UroToday.com) - Background: Oral medications have become more widely available for treatment of various cancers, and adherence to dosing/ refill patterns, or medication possession, are important considerations for treatment.

VAIL, CO USA (UroToday.com) - Background: Factors associated with rates of progression from non-metastatic to metastatic castration resistant prostate cancer (CRPC) have been described.^{[1, 2]}

VAIL, CO USA (UroToday.com) - Background: Abiraterone acetate (AA) and enzalutamide (EN) are two novel oral agents approved for use in docetaxel-treated mCRPC patients.

VAIL, CO USA (UroToday.com) - Background: Clinical guidelines recommend adjuvant radiation therapy (ART) be offered to patients with adverse pathology after radical prostatectomy (RP).

VAIL, CO USA (UroToday.com) - Introduction: Since Clayman performed the first laparoscopic nephrectomy in 1991, laparoscopy has revolutionized operative urology and allowed for marked reductions in postoperative pain and duration of hospital stay.

VAIL, CO USA (UroToday.com) - Background: Radium-223 is a targeted alpha-emitter that selectively binds to bone metastases with high-energy, short-range (< 100 μm) alpha-particles, and is approved by the US Food and Drug Administration and European Commission for treatment of patients with CRPC, symptomatic bone metastases, and no known visceral metastatic disease.

VAIL, CO USA (UroToday.com) - Objectives: Stereotactic Body Radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer.

VAIL, CO USA (UroToday.com) - Background: Short-term antiandrogen (AA) flare protection is used to counter the clinical effects of the testosterone surge associated with luteinizing hormone-releasing hormone (LHRH) agonist therapy.

VAIL, CO USA (UroToday.com) - Background: The cell cycle progression combined risk (CCP-CR) test (Prolaris™, Myriad Genetic Laboratories, Inc.) has been validated in eight cohorts and provides information on the risk of prostate cancer-specific disease progression and disease specific mortality when combined with standard clinicopathologic parameters.